PSMA therapy under more restrictive regimen of 4-week intervals
How oft is the Lu-PSMA treatment conducted? The usual cycle consists of 3 sessions with 6 to 8 weeks interval in-between. Our more restrictive treatment regimen of initial 3 cycles with an interval of only 4 weeks in-between demonstrated >80% response rates even in heavily pre-treated patients. This treatment does not care, “where” the metastases are: lymph nodes, bone,…
Ga-68 demonstrates superiority to F-18 in digital PSMA-PET/CT scans for staging prostate cancer
Fluorine-18 is a commonly used isotope utilized for conducting PSMA-PET/CT to stage prostate cancer, due to its longer half-life and higher production capacity as compared to Gallium-68. The latest study, however, has demonstrated superiority of Ga-68, because of the focal unspecific uptake of F-18 in the bones of ribs and pelvis. Without additional follow-up exams…
PSMA therapy improves health-related quality of life in patients with prostate cancer
On Friday, 17 September 2021, Novartis announced further positive findings from the VISION trial: 177Lu-PSMA-617 therapy delays worsening of physical functioning and the onset of pain symptoms in patients with mCRPC. Hence, beyond extending overall survival and progress-free period, this Breakthrough Therapy also improves health-related quality of life. Read more
NCCN Guidelines add PSMA-PET imaging for prostate cancer
National Comprehensive Cancer Network, an alliance of cancer centers in the US, whose guidelines in oncology are applied to treating cancers, has added 68Ga-PSMA-PET imaging to its clinical practice guidelines for prostate cancer. Moreover, it recognized the high precision of this diagnostic tool as a primary stand-alone method and scrapped conventional imaging as a necessary…
Markus Hartenbach vince il premio Oncology Council’s Young Investigator dell’Associazione Nordamericana di Medicina Nucleare
Markus Hartenbach vince il premio Oncology Council’s Young Investigator dell’Associazione Nordamericana di Medicina Nucleare
Il gruppo di lavoro diretto dal Prof. Markus Hartenbach è stato in grado di dimostrare la superiorità del PSMA PET nella diagnosi della recidiva biochimica del cancro della prostata, anche a bassi livelli di PSA.
Il gruppo di lavoro diretto dal Prof. Markus Hartenbach è stato in grado di dimostrare la superiorità del PSMA PET nella diagnosi della recidiva biochimica del cancro della prostata, anche a bassi livelli di PSA. European Journal of Nuclear Medicine and Molecular Imaging
Il gruppo di lavoro diretto dal Prof. Markus Hartenbach è stato in grado di dimostrare l’eccezionale valore diagnostico del PSMA PET / MRI nel cancro alla prostata sottoposto a biopsia.
Il gruppo di lavoro diretto dal Prof. Markus Hartenbach è stato in grado di dimostrare l’eccezionale valore diagnostico del PSMA PET / MRI nel cancro alla prostata sottoposto a biopsia.
NET Patient Education Conference of NET Research Foundation on Theranostics (PRRT)
Video: Nuclear imaging 68Ga-DOTATATE and PRRT 177Lu-DOTATATE explained (English) NET Patient Education Conference of NET Research Foundation on Theranostics (PRRT), Stanford, US, March 2017
New phase III 177Lu-PSMA-617 trial in mCRPC patients at the stage of antihormonal therapy
New phase III 177Lu-PSMA-617 trial in mCRPC patients who have not undergone chemotherapy.
ASCO 2021: Phase III Study of Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)
The New England Journal of Medicine: “Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer”
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Therapie PSMA
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Radium-223-Therapy (Xofigo®)
Alpha emitter radium-223 and survival in metastatic prostate cancer. Informazioni su Xofigo
PSMA Imaging
68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making
Neuroendocrine Tumors (PRRT)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors Informationen zu Lutathera